Epidermal growth factor receptor (EGFR) is overexpressed in 50–70% of primary rectal cancers [2] and is related to decreased pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS) [3, 4]. This evidence concerns the gene EGFR and rectal cancer.